Cover Image
市場調查報告書

前列腺癌症治療藥的全球市場:2016∼2020年

Global Prostate Cancer Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 318308
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
前列腺癌症治療藥的全球市場:2016∼2020年 Global Prostate Cancer Drugs Market 2016-2020
出版日期: 2016年11月29日 內容資訊: 英文 91 Pages
簡介

前列腺癌,根據美國疾病管理中心,不論人種,成為美國男性的主要死因之一。預計全球的男性每7人有1人發病。男性約每35人有1人死於這個癌症。全球前列腺癌症治療藥市場2016∼2020年的年複合成長率(CAGR)預計達到9.21%。

本報告提供全球的前列腺癌症治療藥的市場相關分析,疾病、治療方法概要和基本的市場結構,藥物開發、臨床實驗的進展,市場規模趨勢(今後5年的預測值),各地區的詳細趨勢,推動、阻礙市場要素與其影響力,主要企業簡介,今後的市場機會等調查、考察。

第1章 摘要整理

第2章 分析範圍

  • 市場概要
  • 主要的產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

第5章 疾病概要

  • 疾病的理解
  • 前列腺癌症的種類
  • 診斷
  • 主要的購買標準

第6章 開發中產品分析

第7章 市場環境

  • 市場概況
  • 波特的五力分析

第8章 各治療法的市場區隔

  • 荷爾蒙療法
  • 化療
  • 免疫療法
  • 標靶治療

第9章 各地區的市場區隔

  • 各地區市場
  • 南北美洲
  • EMEA
  • 亞太地區

第10章 促進市場成長的要素

第11章 推動因素的影響力

第12章 市場課題

第13章 推動因素、課題的影響力

第14章 市場趨勢

第15章 供應商環境

  • 競爭方案

第16章 主要供應商分析

  • Johnson & Johnson
  • Astellas Pharma Inc.
  • AstraZeneca
  • Sanofi
  • AbbVie
  • 其他卓越供應商

第17章 附錄

  • 簡稱集

第18章 關於Technavio

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR10968

About Prostate Cancer Drugs

Prostate cancer is the cancer of prostate gland. According to CDC, it is one of the leading cause of cancer death in men across the races in the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. About one in 35 men die due to prostate cancer. Growth in the prostate can be benign or malignant. Prostate cancer cells spread by breaking away from a prostate tumor. They may travel through blood vessels or lymph vessels and reach other parts of the body. The cells that spread might bind to other tissues, form new tumors, and sometimes damage those tissues as well. When prostate cancer cells spread from their original place to another, the new tumor formed also has the same kind of abnormal cells.

Technavio's analysts forecast the global prostate cancer drugs market to grow at a CAGR of 9.21% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global prostate cancer drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Prostate Cancer Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Johnson & Johnson
  • Sanofi

Other Prominent Vendors

  • Active Biotech
  • ADC Therapeutics
  • Advantagene
  • Advaxis Pharmaceuticals
  • ANI Pharmaceuticals
  • ArQule
  • Athenex Pharmaceuticals
  • Bavarian Nordic
  • Bayer HealthCare
  • BHR Pharma
  • BMS
  • Boehringer Ingelheim
  • Camurus
  • Cleveland BioLabs
  • CureVac
  • Dendreon
  • Dextech Medical
  • Eisai
  • Endo Pharmaceuticals
  • Ferring Pharmaceutical
  • Foresee Pharmaceuticals
  • GlaxoSmithKline
  • GTx
  • Innocrin Pharmaceutical
  • Inspyr Therapeutics
  • Io Therapeutics
  • Lidds AB
  • Merck Group
  • Myovant Sciences
  • Northwest Biotherapeutics
  • Novartis
  • Nymox Pharmaceuticals
  • OncoGenex
  • Oncolytics Biotech
  • Orion
  • Pharmamar
  • Progenics Pharmaceuticals
  • Sotio
  • Spectrum Pharmaceuticals
  • Synta
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical
  • Tokai Pharmaceuticals

Market driver

  • Physicians preference toward adopting hormonal therapies
  • For a full, detailed list, view our report

Market challenge

  • Presence of alternative treatment approaches
  • For a full, detailed list, view our report

Market trend

  • Emergence of targeted therapies and immunotherapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding disease
  • Types of prostate cancer
  • Diagnosis
  • Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape

  • Global prostate cancer therapeutics market
  • Five forces analysis

PART 08: Market segmentation by therapy

  • Hormonal therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted therapy

PART 09: Geographical segmentation

  • Global prostate cancer drugs market by geographical segmentation 2015-2020
  • Prostate cancer drugs market in Americas
  • Prostate cancer drugs market in EMEA
  • Prostate cancer drugs market in APAC

PART 10: Market drivers

  • Physicians preference toward adopting hormonal therapies
  • Development of drugs with novel mechanism of action
  • Availability of large patient pool

PART 11: Impact of drivers

PART 12: Market challenges

  • Presence of alternative treatment approaches
  • High cost of drugs
  • Adverse side-effects of drugs

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

  • Competitive scenario

PART 16: Key vendor analysis

  • Johnson & Johnson
  • Astellas Pharma
  • AstraZeneca
  • Sanofi
  • AbbVie
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key customer segments of global prostate cancer drugs market
  • Exhibit 03: Snapshot of prostate cancer
  • Exhibit 04: Types of prostate cancer
  • Exhibit 05: Main diagnostic procedures to determine presence of prostate cancer
  • Exhibit 06: Key buying criteria for prostate cancer drugs
  • Exhibit 07: Factors affecting the adoption rates of prostate cancer drugs 2015 and 2020
  • Exhibit 08: Pipeline analysis of key vendors in global prostate cancer drugs market
  • Exhibit 09: Percentage share of drug candidates by stage of development
  • Exhibit 10: Phase III pipeline portfolio: Global prostate cancer drugs market
  • Exhibit 11: Phase II pipeline portfolio: Global prostate cancer drugs market
  • Exhibit 12: Phase I pipeline portfolio: Global prostate cancer drugs market
  • Exhibit 13: Global prostate cancer therapeutics market snapshot
  • Exhibit 14: Analysis of global prostate cancer therapeutics market
  • Exhibit 15: Pipeline of global prostate cancer drugs
  • Exhibit 16: Global prostate cancer drugs market 2015-2020 ($ billions)
  • Exhibit 17: Opportunity analysis of global prostate cancer drugs market
  • Exhibit 18: Opportunity analysis in developed and emerging markets
  • Exhibit 19: Five forces analysis
  • Exhibit 20: Segmentation of global prostate cancer drugs market by therapy 2015
  • Exhibit 21: Life cycle analysis of key segments in global prostate cancer drugs market
  • Exhibit 22: Analysis of prostate cancer drugs market by geography
  • Exhibit 23: Segmentation of prostate cancer drugs market based on geography 2015 and 2020
  • Exhibit 24: Prostate cancer drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 25: Prostate cancer drugs market size and forecast in Americas 2015-2020 ($ billions)
  • Exhibit 26: Key trends across various countries in Americas
  • Exhibit 27: Incidence of prostate cancer in key countries of EMEA 2012
  • Exhibit 28: Prostate cancer drugs market size and forecast in EMEA 2015-2020 ($ billions)
  • Exhibit 29: Trends in prostate cancer therapeutics market in EMEA
  • Exhibit 30: Prostate cancer drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 31: Key drivers and challenges in APAC
  • Exhibit 32: Performance of hormone therapies in 2015
  • Exhibit 33: Key drugs with novel mechanism of action
  • Exhibit 34: Potential older population with prostate cancer (65 years and above)
  • Exhibit 35: Impact of drivers
  • Exhibit 36: Alternative therapies
  • Exhibit 37: Costs of key prostate cancer drugs ($ thousands)
  • Exhibit 38: Some of the side-effects of drugs
  • Exhibit 39: Force field analysis of drivers and challenges in global prostate cancer drugs market
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Trend analysis in global prostate cancer drugs market
  • Exhibit 42: Key highlights of targeted therapies and immunotherapies
  • Exhibit 43: New advancements in diagnosis of prostate cancer
  • Exhibit 44: Key late stage pipeline candidates
  • Exhibit 45: Competitive structure analysis of global prostate cancer drugs market 2015
  • Exhibit 46: Market share analysis 2015
  • Exhibit 47: Performance/initiatives of existing and upcoming vendors in global prostate cancer drugs market
  • Exhibit 48: Competitive analysis in global prostate cancer therapeutics market
  • Exhibit 49: Market penetration of various prostate cancer drug manufacturers worldwide 2015
  • Exhibit 50: Regional analysis of vendors in global prostate cancer drugs market
  • Exhibit 51: Johnson & Johnson: Key highlights
  • Exhibit 52: Johnson & Johnson: Strength assessment
  • Exhibit 53: Johnson & Johnson: Strategy assessment
  • Exhibit 54: Johnson & Johnson: Opportunity assessment
  • Exhibit 55: Johnson & Johnson: YoY revenue comparison of Zytiga (Global) 2013-2015 ($ billions)
  • Exhibit 56: Astellas Pharma: Key highlights
  • Exhibit 57: Astellas Pharma: Strength assessment
  • Exhibit 58: Astellas Pharma: Strategy assessment
  • Exhibit 59: Astellas Pharma: Opportunity assessment
  • Exhibit 60: Astellas Pharma: YoY revenue comparison of Xtandi 2014-2015 ($ billions)
  • Exhibit 61: AstraZeneca: Key highlights
  • Exhibit 62: AstraZeneca: Strength assessment
  • Exhibit 63: AstraZeneca: Strategy assessment
  • Exhibit 64: AstraZeneca: Opportunity assessment
  • Exhibit 65: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions)
  • Exhibit 66: AstraZeneca: Geographic segmentation of Zoladex 2015
  • Exhibit 67: AstraZeneca: YoY revenue and growth rate of Casodex 2013-2015 ($ millions)
  • Exhibit 68: AstraZeneca: Geographic segmentation of Zoladex 2015
  • Exhibit 69: Sanofi: Key highlights
  • Exhibit 70: Sanofi: Strength assessment
  • Exhibit 71: Sanofi: Strategy assessment
  • Exhibit 72: Sanofi: Opportunity assessment
  • Exhibit 73: Sanofi: YoY revenue and growth rate of Jevtana 2013-2015 ($ millions)
  • Exhibit 74: Sanofi: YoY revenue and growth rate of Taxotere 2013-2015 ($ millions)
  • Exhibit 75: AbbVie: Key highlights
  • Exhibit 76: AbbVie: Strength assessment
  • Exhibit 77: AbbVie: Strategy assessment
  • Exhibit 78: AbbVie: Opportunity assessment
  • Exhibit 79: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)
Back to Top